View
213
Download
0
Category
Preview:
Citation preview
www.virology-education.com
MEETING PROSPECTUS
1ST EUROPEAN MEETING ON
HepCure
European
FRANKFURT, GERMANY • 9 - 10 SEPTEMBER 2015
HEPATITIS CURE & ERADICATION
HepCure
European
21st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
CONTENT
Workshop description ........................................................................... 4
Background .............................................................................................4
Meeting Objectives ..................................................................................4
Format ....................................................................................................4
Unique Meeting Features .......................................................................4
Target audience ......................................................................................4
Organizing Committee .......................................................................... 5
Scientific Committee ............................................................................ 6
Program outline 2015 ........................................................................... 7
Meeting demographics 2014 ................................................................ 8
Participants’ feedback 2014 .................................................................. 9
HepCure
European
31st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
INTRODUCTION
It is our pleasure to invite you for the 1st European Hepatitis Cure & Eradication meeting, which will take place in Frankfurt, Germany on 9 and 10 September 2015.
The field of Hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately eradication and cure of Viral Hepatitis B and C.
On 9 & 10 september 2015, we will be organizing an international platform to decrease the burden of the disease, to simplify treatment and to cure and eradicate Hepatitis, involving many prominent stakeholders. This public health program addresses awareness and underdiagnosis and undertreatment of viral hepatitis. This state-of-the-art meeting will take place in Frankfurt, Germany
The format of this workshop will consist of a one-and-a-half day translational meeting with state-of-the-art lectures, roundtable discussions and debates. In order to ascertain an interactive workshop setting, much time will be allocated to Q&A and discussion.
This meeting prospectus is designed in order to provide information on the meeting set up and program. We hope this information is of interest. Please contact us if specific information is missing and we will gladly provide you with additional documentation.
The Organizing Committee
HepCure
European
41st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
WORKSHOP DESCRIPTION
BACKGROUNDThe field of Hepatitis treatment is undergoing major changes and is on the verge of a paradigm shift. The many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately eradication and cure of Viral Hepatitis B and C.
In order to reach this end goal of cure for Hepatitis, many studies still need to be performed and interpreted. Therefore, to enhance this field of research, we feel there is a need for a state of the art, independent and interactive platform for scientific exchange between hepatitis experts worldwide.
Certainly investigators have the possibility to submit their research in this area to major international conferences, but there is usually limited time for in-depth discussion and debate among experts on new data and their implications.
Goal: defining the pathway forward to cure and eradicate viral hepatitis from the world
MEETING OBJECTIVES• Identify the roadblocks and the challenges to come to an European approach to cure and eradicate viral hepatitis.
• Identify the needs from the public health perspective
• Get a cross-disciplinary discussion started
• Create a platform for collaboration and national action plans.
FORMATThe format of this workshop will consist of a one-and-a-half day translational meeting with invited lectures. In order to ascertain an interactive workshop setting, much time will be allocated to Q&A sessions, roundtable discussions and debates.
UNIQUE MEETING FEATURESThe many new treatment options that are becoming available through the introduction of Direct Acting Antivirals are providing great hopes for decreasing the burden of disease and simplifying treatment and ultimately eradication and cure of Viral Hepatitis B and C.
In order to reach this end goal of cure for Hepatitis, many studies still need to be performed and interpreted. The International Hepatitis Cure & Eradication Meeting offers a unique platform to discuss what needs to be done now in order to cure and eradicate Hepatitis in the future.
TARGET AUDIENCEThe 1st European Hepatitis Cure & Eradication Meeting 2015 brings together clinicians involved in daily care, academic researchers, policy makers and industry representatives supporting the goal of this meeting.
HepCure
European
51st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
ORGANIZING COMMITTEE
HATZAKIS ANGELOS, MD, PHD
University of Athens, Greece
CARLO PERNO, MD, PHD
University of Rome Tor Vergata, Italy
JEAN-MICHEL PAWLOTSKY, MD, PHD
Hôpital Henri Mondor, France
HARRY JANSSEN, MD
University of Toronto, Canada
GRAHAM FOSTER, FRCP, PHD
Queen Mary, University of London United Kingdom
HEINER WEDEMEYER, MD
Medical School Hannover, Germany
STEFAN ZEUZEM, MD
JW Goethe University Hospital, Germany
CHARLES BOUCHER, MD, PHD
Erasmus Medical Center Rotterdam, the Netherlands
HepCure
European
61st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
SCIENTIFIC COMMITTEE
Robert Brown ................................................................. University of Missouri, School of Medicine, USA
Maria Butí ...................................................................................................... Hospital Vall’ Hebron, Spain
Milagros Davalos ............................................................ Universidad de Ciências Aplicadas (UCP), Peru
Raffaele De Francesco ...........................................................................................Fondazione INGM, Italy
Rafael Esteban ................................................................................................ Hospital Vall’Hebron, Spain
Peter Ferenci ................................................................................................ University of Vienna, Austria
Margaret Hellard ............................ Burnet Institute for Medical Research and Public Health, Australia
Marina Klein ................................................................................McGillUniversity Health Centre, Canada
Mel Krajden ..................................................................................BC Centre for Disease Control, Canada
Karine Lacombe .........................Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, France
Geoff McCaughan ........................................ University of Sydney Royal Prince Alfred Hospital, Australia
Mark Nelson ...........................................................Chelsea and Westminster Hospital, United Kingdom
Jean-Michel Pawlotsky .............................................. Hôpital Henri Mondor, Université Paris XII, France
Stanislas Pol .......................................................................................................... Hôpital Cochin, France
Massimo Puoti ..................................................................................................University of Brescia, Italy
Robert Ralston .........................................................................University of Kansas Medical Center, USA
Charles Rice ....................................................................................................Rockefeller University, USA
Dominique Salmon ................................................................................................ Hôpital Cochin, France
Mauro Schechter ...................................................................Federal University of Rio de Janeiro, Brazil
Vincent Soriano ................................................................................................... Hospital Carlos III, Spain
James Trotter ................................................................................ Baylor University Medical Center, USA
Fu-Sheng Wang................................................................................................Beijing 302 Hospital, China
Hui Zhuang ..................................................................... Peking University Health Science Centre, China
Fabien Zoulim ...................................................................................................................INSERM, France
HepCure
European
71st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
PROGRAM 2015
PROGRAMThe program is currently under development.
The aim of the Organizing Committee is to intermix basic science, clinical medicine and public health issues within the sessions.
This format will emphasize the importance of a broader cohesive response, ensuring that all key holders hear and understand the breadth of cure and eradication of viral hepatitis.
HepCure
European
81st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
MEETING DEMOGRAPHICS 2014
NUMBER OF PARTICIPANTS146 participants from 14 countries attended the meeting.
The geographical distribution of participants is as follows:
Australia 3
Austria 1
Belgium 1
Canada 112
China 1
Egypt 1
Germany 2
Italy 2
Japan 1
Nigeria 1
Switzerland 2
The Netherlands 5
United Kingdom 4
USA 10
PROFESSIONAL BACKGROUNDMain activity Mainly employed by:
Area of expertise:
HepCure
European
91st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
PARTICIPANTS’ FEEDBACK 2014
This is the evaluation report of the 1st Hepatitis Cure & Eradication Meeting, held on 5 - 6 November 2014 in Toronto, Canada. The Organizing Commitee and the Organizing Secretariat highly value the opinion of the participants in order to further improve the quality of the workshop. Participants were asked to complete an evaluation form to share their opinion on several subjects.
On the first day 51 participants completed the evaluation form (35%). On the second day the organizers have been able to collect 72 completed forms (49%).
PERSONAL BENEFITS97,5% of the respondents indicated they will recommend this workshop to their colleagues. Whether they will attend again mainly depends on the location of next year’s edition:
I plan to attend this workshop again next year, if it is being organized prior to the AASLD: 83,1% I plan to attend this workshop again next year, if it is being organized as a stand-alone meeting (in Europe): 43,2% I plan to attend this workshop again next year, if it is being organized as a stand-alone meeting (in North-America): 78,8%
CONTENTVery much
agree
Agree Neutral Disagree Very much
disagree
The content of the meeting met my expectations 44,3% 45,7% 8,6% 1,4% 0,0%
Sufficient time allocated for discussion during the meeting 60,9% 33,3% 2,9% 2,9% 0,0%
The allocated time per presentation was sufficient 57,7% 36,6% 4,2% 1,4% 0,0%
I perceived no commerial bias at the workshop 58,0% 30,4% 8,7% 0,0% 0,0%
HepCure
European
101st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
PARTICIPANTS’ FEEDBACK 2014
LECTURES
WEDNESDAY 5 NOVEMBER Opening session
Keynote Lecture: The Evolution of Treating Viral Hepatitis
R. Schinazi
Excellent Good Average Fair Poor
Content 51,2% 39,5% 7% 2,3% 0,0%
Presentation 42,9% 42,9% 11,9% 2,4% 0,0%
Towards a cure for Hepatitis B: Inspiration from HIV
D. Hazuda
Excellent Good Average Fair Poor
Content 34,1% 45,5% 13,6% 6,8% 0,0%
Presentation 37,2% 37,2% 18,6% 7,0% 0,0%
Session 1: Hepatitis B – from Control to Cure (part 1)
State of the Art of Hepatitis B Treatment
P. Lampertico
Excellent Good Average Fair Poor
Content 64,6% 31,3% 4,2% 0,0% 0,0%
Presentation 72,3% 23,4% 4,3% 0,0% 0,0%
New HBV Treatment Options on the Horizon
H. Janssen
Excellent Good Average Fair Poor
Content 49,0% 44,9% 6,1% 0,0% 0,0%
Presentation 50,0% 43,8% 6,3% 0,0% 0,0%
Does Viral Cure Prevent HCC Development
H. Chan
Excellent Good Average Fair Poor
Content 56,3% 31,3% 12,5% 0,0% 0,0%
Presentation 51,1% 38,3% 8,5% 2,1% 0,0%
Session 2: Hepatitis B – from Control to Cure (part 2)
How to Achieve Cure in HBV: A Virological Perspective
S. Locarnini
Excellent Good Average Fair Poor
Content 61,7% 31,9% 4,3% 2,1% 0,0%
Presentation 52,1% 39,6% 8,3% 0,0% 0,0%
How to Achieve Cure in HBV: An Immunological Perspective
A. Gehring
Excellent Good Average Fair Poor
Content 68,1% 25,5% 6,4% 0,0% 0,0%
Presentation 70,2% 25,5% 4,3% 0,0% 0,0%
HepCure
European
111st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
PARTICIPANTS’ FEEDBACK 2014
How to Achieve Cure in HBV: A Clinical Perspective
H. Wedemeyer
Excellent Good Average Fair Poor
Content 68,9% 22,2% 8,9% 0,0% 0,0%
Presentation 68,9% 20,0% 8,9% 2,2% 0,0%
THURSDAY 6 NOVEMBER
Session 3: Hepatitis C – Curing the Patient (part 1)
Current Treatment Challenges
T. Berg
Excellent Good Average Fair Poor
Content 34,9% 50,8% 14,3% 0,0% 0,0%
Presentation 32,8% 51,6% 15,6% 0,0% 0,0%
Treatment in Special Clinical Populations
J. Feld
Excellent Good Average Fair Poor
Content 62,1% 30,3% 7,6% 0,0% 0,0%
Presentation 64,6% 29,2% 6,2% 0,0% 0,0%
Session 4: Hepatitis C – Curing the Patient (part 2)
An HCV Vaccine: Can We Get There?
A. Cox
Excellent Good Average Fair Poor
Content 58,2% 28,4% 13,4% 0,0% 0,0%
Presentation 55,9% 35,3% 8,8% 0,0% 0,0%
Role of Virus Control in Development of HCC
M. Sherman
Excellent Good Average Fair Poor
Content 29,0% 52,2% 13,0% 5,8% 0,0%
Presentation 33,3% 46,4% 14,5% 5,8% 0,0%
Session 5: From Cure to Eradication
Current Prevention Strategies of Viral Hepatitis
K. Mitruka
Excellent Good Average Fair Poor
Content 45,7% 37,1% 17,1% 0,0% 0,0%
Presentation 47,1% 40,0% 12,9% 0,0% 0,0%
Global Underdiagnosis of Viral Hepatitis M. Krajden
Excellent Good Average Fair Poor
Content 37,1% 45,7% 15,7% 1,4% 0,0%
Presentation 35,7% 45,7% 17,1% 1,4% 0,0%
HepCure
European
121st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
Linkage of Care
S. Mehta
Excellent Good Average Fair Poor
Content 62,9% 24,3% 12,9% 0,0% 0,0%
Presentation 65,2% 26,1% 8,7% 0,0% 0,0%
Session 6: Treatment as Prevention
Experience in HIV
J. Montaner
Excellent Good Average Fair Poor
Content 49,3% 34,3% 16,4% 0,0% 0,0%
Presentation 53,0% 33,3% 13,6% 0,0% 0,0%
Challenges in HBV
H. Chan
Excellent Good Average Fair Poor
Content 33,8% 44,6% 18,5% 3,1% 0,0%
Presentation 34,4% 48,4% 17,2% 0,0% 0,0%
Challenges in HCV
G. Dore
Excellent Good Average Fair Poor
Content 55,4% 35,4% 9,2% 0,0% 0,0%
Presentation 54,7% 34,4% 10,9% 0,0% 0,0%
Session 7: Delivering Therapy on an Individual & Society Level
Integrative talk
C. Gore
Excellent Good Average Fair Poor
Content 49,2% 39,0% 11,9% 0,0% 0,0%
Presentation 50,0% 43,1% 6,9% 0,0% 0,0%
The Role of the WHO
S. Wiktor
Excellent Good Average Fair Poor
Content 40,4% 43,9% 15,8% 0,0% 0,0%
Presentation 37,5% 51,8% 10,7% 0,0% 0,0%
The Role of the Pharmaceutical industry J. Rooney
Excellent Good Average Fair Poor
Content 35,8% 39,6% 18,9% 0,0% 5,7%
Presentation 34,0% 39,6% 20,8% 1,9% 3,8%
The Role of the Medical community
G. Dusheiko
Excellent Good Average Fair Poor
Content 36,7% 38,8% 20,4% 4,1% 0,0%
Presentation 38,8% 28,6% 28,6% 4,1% 0,0%
The Role of the Medical community
M. El-Sayed
Excellent Good Average Fair Poor
Content 68,8% 22,9% 4,2% 4,2% 0,0%
Presentation 71,4% 18,4% 6,1% 4,1% 0,0%
HepCure
European
131st European Hepatitis Cure & Eradication Meeting 2015 9 - 10 september 2015, Frankfurt, Germany
The Role of the Patients
C. Gore
Excellent Good Average Fair Poor
Content 44,9% 32,7% 18,4% 4,1% 0,0%
Presentation 42,9% 34,7% 20,4% 2,0% 0,0%
The Role of the CDC USA
K. Mitruka
Excellent Good Average Fair Poor
Content 47,9% 31,3% 18,8% 2,1% 0,0%
Presentation 44,7% 34,0% 19,1% 2,1% 0,0%
Presentation of the Toronto Declaration on Global Eradication of Hepatitis
J. Feld
Excellent Good Average Fair Poor
Content 65,8% 28,9% 5,3% 0,0% 0,0%
Presentation 63,2% 28,9% 7,9% 0,0% 0,0%
Recommended